Scarica l'app Stockscreener
1.14
0.87%
-0.01
Dopo l'orario di chiusura:
1.13
-0.01
-0.88%
Precedente Chiudi:
$1.15
Aprire:
$1.13
Volume 24 ore:
371.62K
Relative Volume:
1.64
Capitalizzazione di mercato:
$11.50M
Reddito:
$200.00K
Utile/perdita netta:
$-11.37M
Rapporto P/E:
-0.4134
EPS:
-2.7573
Flusso di cassa netto:
$-10.27M
1 W Prestazione:
-5.79%
1M Prestazione:
-2.56%
6M Prestazione:
-10.94%
1 anno Prestazione:
-48.42%
Intervallo 1D:
$1.10
$1.17
Intervallo di 1 settimana:
$1.06
$1.225
Portata 52W:
$1.00
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Nome
Soligenix Inc
Settore
Industria
Telefono
609-538-8200
Indirizzo
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.14 | 11.50M | 200.00K | -11.37M | -10.27M | -2.7573 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-28 | Downgrade | Dawson James | Buy → Neutral |
| 2018-01-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | Reiterato | Maxim Group | Buy |
| 2017-07-17 | Iniziato | H.C. Wainwright | Buy |
Soligenix Inc Borsa (SNGX) Ultime notizie
[EFFECT] SOLIGENIX, INC. SEC Filing - Stock Titan
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy - Sahm
Soligenix (SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy - NewMediaWire
Soligenix (SNGX) Announces Positive Study Results for HyBryte in CTCL Treatment - GuruFocus
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy - TradingView
HyBryte study shows faster response vs Valchlor in lymphoma trial By Investing.com - Investing.com Canada
Soligenix (SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results - NewMediaWire
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results - tipranks.com
Soligenix reports 2025 results, eyes Q2 trial data By Investing.com - Investing.com South Africa
Soligenix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Soligenix (NASDAQ: SNGX) registers 1,054,688 resale shares from warrants - Stock Titan
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Soligenix (SNGX) 2025 10-K outlines CTCL, psoriasis and vaccine programs - Stock Titan
Buybacks Report: Can Soligenix Inc grow without external funding2026 Volatility Report & Safe Entry Trade Reports - baoquankhu1.vn
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results - Bitget
Soligenix reports 2025 results, eyes Q2 trial data - Investing.com
Soligenix announces recent accomplishments and year end 2025 financial results - marketscreener.com
Soligenix Announces Recent Accomplishments And Year End 2025 Financial Results - TradingView
Retail Trends: What analysts say about Soligenix Inc stockGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn
Aug Sectors: Is Soligenix Inc a strong candidate for buy and holdMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Guidance Update: Will Soligenix Inc benefit from rising consumer demand2026 Highlights & AI Forecasted Stock Moves - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
Soligenix receives EU orphan drug status for Behçet’s treatment By Investing.com - Investing.com South Africa
Soligenix (SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behcet Disease - NewMediaWire
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease - Benzinga
Soligenix (SNGX) Gains EU Orphan Drug Designation for Dusquetide in Behcet's Disease - GuruFocus
Soligenix receives EU orphan drug status for Behçet’s treatment - Investing.com
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease - Lelezard
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behcet's Disease - Bitget
Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - NewMediaWire
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - TradingView
Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting - NewMediaWire
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting - Benzinga
Soligenix (SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - NewMediaWire
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - TipRanks
HyBryte Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - Finviz
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - Nasdaq
If You Invested $1,000 in Soligenix Inc (SNGX) - Stock Titan
Soligenix (SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication - NewMediaWire
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication - Digital Journal
Soligenix (SNGX) Highlights HyBryte's Promise in Treating Early-Stage CTCL - GuruFocus
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times
IBN Announces Latest Episode of The BioMedWire Podcast - GlobeNewswire
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" - Nasdaq
Soligenix Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Soligenix Inc Azioni (SNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):